The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

J Gastroenterol Hepatol. 2018 Jan;33(1):86-98. doi: 10.1111/jgh.13856.

¹ Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
³ State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong.
⁴ Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
⁵ Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong.
⁶ University of Santo Tomas, Manila, Philippines.
⁷ Hepatitis Research Center, National Taiwan University, Taipei, Taiwan.
⁸ Department of Internal Medicine, Hepatitis Research Center, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
⁹ Digestive Disease and GI Oncology Centre, Medistra Hospital, Jakarta, Indonesia.
¹⁰ Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
¹¹ Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
¹² Department of Diabetology, Kameoka Municipal Hospital, Kameoka, Japan.
¹³ Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
¹⁴ Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
¹⁵ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

No abstract available

Keywords: NAFLD; NASH; metabolic syndrome; non-alcoholic steatohepatitis; obesity; obeticholic acid; pioglitazone; vitamin E.

Publication types